Mycobax Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of non-tuberculous mycobacterial infections, limited effectiveness of conventional antibiotic therapies, growing prevalence of bronchiectasis and cystic fibrosis, expansion of clinical research in immunotherapy, rising awareness of chronic pulmonary infections.

The growth in the forecast period can be attributed to increasing investment in novel immunotherapies, growing demand for alternatives to long-term antibiotics, expansion of personalized infection management, rising clinical trial activity for ntm vaccines, increasing focus on immune-based disease control. Major trends in the forecast period include increasing development of immunomodulatory therapies for ntm infections, rising focus on chronic lung disease management, growing interest in bcg-based immunotherapies, expansion of investigational vaccine pipelines, enhanced emphasis on treatment for drug-resistant infections.

The growing incidence of tuberculosis is expected to drive the growth of the Mycobax market going forward. Tuberculosis is a highly contagious infectious disease caused by *Mycobacterium tuberculosis*, primarily affecting the lungs but potentially impacting other organs. The rising incidence of tuberculosis is driven by factors such as overcrowding, poor sanitation, increased HIV co-infections, and the emergence of multidrug-resistant (MDR) TB strains. Mycobax is designed to provide effective immunity against *Mycobacterium tuberculosis*, particularly in regions where BCG vaccine efficacy is limited. For instance, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Therefore, the growing incidence of tuberculosis is driving the growth of the Mycobax market.

The surge in the number of newborn babies is expected to propel the growth of the Mycobax market. The global birth rate is rising due to improved healthcare, reduced infant mortality, and higher birth rates in certain regions. Mycobax provides safe and effective tuberculosis (TB) prevention for infants, offering early protection in vulnerable populations. For instance, in July 2024, database.earth, a US-based data platform, reported that in 2025, approximately 132,399,173 babies are expected to be born worldwide, with 34,085,338 male and 29,050,646 female. Therefore, the surge in newborns is driving the growth of the Mycobax market.

The increasing healthcare infrastructure is expected to propel the growth of the Mycobax market. Healthcare infrastructure includes the essential facilities, resources, and systems needed to deliver quality healthcare, such as hospitals, clinics, medical equipment, and trained personnel. Growth in healthcare infrastructure is driven by factors such as a rising global population, urbanization, and an aging demographic. Expanded healthcare infrastructure enables Mycobax to integrate effectively into vaccination programs in high-risk regions, providing a strong preventive tool against tuberculosis. For instance, in May 2023, the American Health Care Association, a US-based nonprofit, reported that the United States had 6,129 hospitals, a 0.591% increase from 6,093 hospitals the previous year. Therefore, the increasing healthcare infrastructure is driving the growth of the Mycobax market.

Major companies operating in the mycobax market are Sanofi Pasteur Ltd.

North America was the largest region in the mycobax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycobax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycobax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the mycobax market by increasing costs of imported biological substrates, formulation materials, laboratory reagents, and specialized clinical trial supplies used in vaccine development. Research institutions and biotechnology firms in North America and Europe are most affected due to reliance on global research supply chains, while emerging regions face higher barriers to trial expansion. These tariffs are increasing development expenses and extending timelines. However, they are also encouraging localized research manufacturing, regional sourcing of biologic inputs, and investment in domestic biopharmaceutical innovation ecosystems.

The mycobax market research report is one of a series of new reports that provides mycobax market statistics, including mycobax industry global market size, regional shares, competitors with a mycobax market share, detailed mycobax market segments, market trends and opportunities, and any further data you may need to thrive in the mycobax industry. This mycobax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mycobax is an investigational vaccine based on Bacillus Calmette-Guérin (BCG), developed as an immunotherapy for managing non-tuberculous mycobacterial (NTM) infections. The vaccine works by modulating the immune system to enhance the body’s ability to combat chronic and often drug-resistant lung infections, which are especially common in individuals with underlying conditions such as bronchiectasis or cystic fibrosis.

The primary indications for Mycobax are tuberculosis prevention and post-exposure prophylaxis. Tuberculosis prevention involves using medical interventions, including vaccines or treatments, to stop the spread of TB. The vaccine is available in formulations such as injectable solution and lyophilized powder for reconstitution and is distributed through hospitals, public health clinics, pharmacies, and mobile vaccination units. It is used in infants, children, and adults.

The mycobax market consists of the sales of mycobax detection systems, mycobax polymerase chain reaction (PCR) kits, and mycobax environmental testing kits. Values in this market are ‘factory gate’ values, representing the value of goods sold by manufacturers directly to other entities (such as downstream manufacturers, wholesalers, distributors, retailers, or end customers). The market value includes related services provided by the vaccine developers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.